Lars Green

Cerebriu’s proven radiology AI solutions detect findings during the initial scan and enable the most appropriate procedures while the patient is still in the scanner. This leads to a simpler, faster MR image acquisition and creates tangible clinical value: Improving technologists’ confidence and freeing up radiologists’ time by ensuring the right data the first time the patient is in the scanner Timely diagnosis of critical findings by prioritizing radiologists’ worklists Improving patient experience and reducing patient recalls

First professional American football team in the Nordics | Based in Copenhagen/Malmö 🇩🇰🇸🇪

Novozymes has combined with Chr. Hansen to become Novonesis: linkedin.com/company/novonesis. This global biosolutions company of 10,000 people is transforming how the world produces, consumes and lives. In 30-plus industries, its biosolutions help businesses meet their needs and the needs of our planet. Novozymes was formed in 2000 when Novo Nordisk split into three companies: Novo Nordisk A/S, Novozymes A/S and Novo A/S. Novozymes was the world leader in biological solutions with a commitment to Rethink Tomorrow. It served 130 markets with enzymatic, microbial and advanced protein solutions. The company’s solutions enabled higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits. In December 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner by combining the two companies. The goal was to unleash the full potential of biosolutions and generate significant value for all stakeholders and society. The combination was completed on January 29, 2024 and Novonesis was born. The name means ‘a new beginning’ and is derived from the Greek word ‘genesis’. It reflects a new era where we’ll better our world with biology. You can find Novonesis on LinkedIn here: linkedin.com/company/novonesis. Novozymes A/S, part of Novonesis Group.

Cerebriu’s proven radiology AI solutions detect findings during the initial scan and enable the most appropriate procedures while the patient is still in the scanner. This leads to a simpler, faster MR image acquisition and creates tangible clinical value: Improving technologists’ confidence and freeing up radiologists’ time by ensuring the right data the first time the patient is in the scanner Timely diagnosis of critical findings by prioritizing radiologists’ worklists Improving patient experience and reducing patient recalls

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S and manages an investment portfolio, with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, Principal and Planetary Health Investments teams, Novo Holdings invests in life science companies at all stages of development.

The vision of the Novo Nordisk Foundation is to improve people’s health and the sustainability of society and the planet. The Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives established in Denmark in 1924. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.

First professional American football team in the Nordics | Based in Copenhagen/Malmö 🇩🇰🇸🇪

Pharmacosmos is considered a world leading authority in treatment of iron deficiency anaemia. Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use. A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time. Pharmacosmos has affiliates in the US, China, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.